Document is current
Any future updates will be listed below
-
Authors
Fidler, Trevor P. https://orcid.org/0000-0002-0758-9984
Dunbar, Andrew
Kim, Eunyoung https://orcid.org/0000-0002-9749-9930
Hardaway, Brian
Pauli, Jessica
Xue, Chenyi
Abramowicz, Sandra
Xiao, Tong https://orcid.org/0000-0003-1462-4650
O’Connor, Kavi https://orcid.org/0009-0008-0830-3731
Sachs, Nadja
Wang, Nan https://orcid.org/0000-0001-9976-0859
Maegdefessel, Lars https://orcid.org/0000-0001-5228-2634
Levine, Ross https://orcid.org/0000-0002-7884-1905
Reilly, Muredach https://orcid.org/0000-0002-3035-9386
Tall, Alan R. https://orcid.org/0000-0002-7708-2417
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (F32HL151051, R00HL157649, HL155431, HL170157, HL107653)
Damon Runyon Cancer Research Foundation (PST-24-19)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA197594, P30 CA008748)
Fondation Leducq (TNE-18CVD04)
- License Information
-
More Information
Article History
Received: 17 April 2023
Accepted: 30 November 2023
First Online: 11 January 2024
Competing interests
: R.L. is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Zentalis, Ajax, Auron, Prelude, C4 Therapeutics and Isoplexis. He receives research support from Ajax and Zentalis and has consulted for Incyte, Janssen, Astra Zeneca and Novartis. He has received honoraria from Astra Zeneca, Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews. A.R.T. is on the SABs of Tensixteen Bio, and Beren Pharmaceuticals. A.D. has served on an advisory committee for Incyte. L.M. is a scientific consultant and medical advisor for Roche Diagnostics, Novo Nordisk and DrugFarm Inc., and is an advisory board member of Angiolutions. He further received research funding from Roche Diagnostics and Novo Nordisk. The remaining authors declare no competing interests.
